Acquired hypothyroidism (disorder)
NCA002 - Tissue and Fluid Banking in Idiopathic Normal Pressure Hydrocephalus
Year Started: 2019
NCARC has a growing collection of blood and cerebrospinal fluid samples in patients with idiopathic normal pressure hydrocephalus (iNPH). There is an associated research database with clinical, neuropsychological and imaging data. iNPH lacks a good understanding of the cause of the condition. The iNPH collection aims to promote research into the discovery of new biomarkers by providing biomaterial to academic and commercial researchers/partners, to enable investigation into the underlying cause of the condition using the most advanced scientific methods thereby improving diagnosis and treatment.
- Access:
- Open to applicants
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- Other animal work restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Primary care records | 0 - 3 months |
Survey data | 0 - 3 months |
Treatment records | 0 - 3 months |
Warm ischemic time | 0 - 3 months |
Donor Ethnicity | 0 - 3 months |
Female
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Whole blood | -60°C to -85°C | Not applicable | 100% | ||
Serum | -60°C to -85°C | Not applicable | 100% | ||
Plasma | -60°C to -85°C | Not applicable | 100% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 26 - 50% | ||
Cerebrospinal fluid | -60°C to -85°C | Not applicable | 75% -99% |
Distal spinal muscular atrophy (disorder)
NCA013 - Adult Spinal Muscular Atrophy (SMA) Collection
Year Started: 2020
This collection of cerebrospinal fluid, serum, plasma and whole blood samples from people with Spinal Muscular Atrophy (SMA) includes baseline samples prior to treatment and follow-up samples collected after commencement of medications such as nusinersen. SMA is a devastating neurological disease. Patients suffer from progressive wasting and weakness with a significant effect on quality of life, as well as an increase morbidity and mortality. Whilst genetic underpinnings of this disease is not yet determined. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research of why SMA occurs. These samples could be used to deepen our understanding of the cause of SMA, help understand why some patients are affected by the condition more than others and find biomarkers of early treatment response. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): • Biomarker studies • Immunological studies • Multi-morbidity studies • Functional analysis of cells
- Access:
- Open to applicants
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- Other animal work restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Primary care records | 0 - 3 months |
Survey data | 0 - 3 months |
Treatment records | 0 - 3 months |
Warm ischemic time | 0 - 3 months |
Donor Ethnicity | 0 - 3 months |
Female
Young adult (18 - 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Whole blood | -60°C to -85°C | Not applicable | 100% | ||
Serum | -60°C to -85°C | Not applicable | 100% | ||
Plasma | -60°C to -85°C | Not applicable | 100% | ||
Cerebrospinal fluid | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Whole blood | -60°C to -85°C | Not applicable | 100% | ||
Serum | -60°C to -85°C | Not applicable | 100% | ||
Plasma | -60°C to -85°C | Not applicable | 100% | ||
Cerebrospinal fluid | -60°C to -85°C | Not applicable | 75% -99% |
COVID-19
NCA009 Covid-19 Collection
Year Started: 2020
The Covid-19 collection consists of blood, serum, saliva, sputum, nasal strips, nasopharyngeal & oropharyngeal swabs and pleural fluid from patients infected with the novel coronavirus. In some cases, longitudinal samples have and will be collected, which could include samples prior to or after infections with Covid-19. The Covid-19 collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research to answer a range of questions including: • How does Covid-19 make some people severely unwell? • Does our immune system protect us from re-infection with COVID-19 after we have recovered from infection? • How well do tests for Covid-19 work? • What are the best ways to identify or test for Covid-19? • How does the body respond throughout the course of infection, recovery and possible reinfection? • How long does our immune system protects us from re-infection with Covid-19 after we have recovered from infection? • How does the immune system contribute to long-term post viral symptoms? The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • The effects of long Covid-19 • Biomarker studies • Immunological studies • Multi-morbidity studies • Functional analysis of cells of the respiratory system
- Access:
- Open to applicants
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- Other animal work restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Primary care records | 0 - 3 months |
Survey data | 0 - 3 months |
Treatment records | 0 - 3 months |
Warm ischemic time | 0 - 3 months |
Donor Ethnicity | 0 - 3 months |
Female
Young adult (18 - 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Whole blood | -60°C to -85°C | Not applicable | 100% | ||
Serum | -60°C to -85°C | Not applicable | 100% | ||
Plasma | -60°C to -85°C | Not applicable | 100% | ||
Swab | -60°C to -85°C | Not applicable | 100% | ||
Saliva | -60°C to -85°C | Not applicable | 75% -99% | ||
Pleural fluid PFL | -60°C to -85°C | Not applicable | 75% -99% | ||
Cerebrospinal fluid | -60°C to -85°C | Not applicable | 11 - 25% | ||
Sputum | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Whole blood | -60°C to -85°C | Not applicable | 100% | ||
Serum | -60°C to -85°C | Not applicable | 100% | ||
Plasma | -60°C to -85°C | Not applicable | 100% | ||
Swab | -60°C to -85°C | Not applicable | 100% | ||
Saliva | -60°C to -85°C | Not applicable | 75% -99% | ||
Pleural fluid PFL | -60°C to -85°C | Not applicable | 75% -99% | ||
Sputum | -60°C to -85°C | Not applicable | 75% -99% | ||
Cerebrospinal fluid | -60°C to -85°C | Not applicable | 11 - 25% |